30.17
price down icon3.15%   -0.98
after-market アフターアワーズ: 30.17
loading

Ionis Pharmaceuticals Inc (IONS) 最新ニュース

pulisher
10:01 AM

Assessing Ionis Pharmaceuticals: Insights From 8 Financial Analysts - Benzinga

10:01 AM
pulisher
07:51 AM

Redburn Atlantic Initiates Ionis Pharmaceuticals at Neutral With $39 Price Target - MarketScreener

07:51 AM
pulisher
07:05 AM

Ionis to present at upcoming investor conferences - The Joplin Globe

07:05 AM
pulisher
07:05 AM

Ionis Secures Triple Conference Spotlight: Key Investor Events Announced for Spring 2025 - Stock Titan

07:05 AM
pulisher
05:40 AM

Redburn initiates Ionis stock with Neutral, sets $39 target - Investing.com India

05:40 AM
pulisher
Mar 30, 2025

11 Best Gene Therapy Stocks to Buy According to Analysts - Insider Monkey

Mar 30, 2025
pulisher
Mar 30, 2025

IONS Out-Licenses ex-U.S. Rights for Rare Disease Drug Tryngolza to Sobi - MSN

Mar 30, 2025
pulisher
Mar 29, 2025

Ionis expands partnership with Sobi to include olezarsen commercialization outside the U.S. - MSN

Mar 29, 2025
pulisher
Mar 28, 2025

Catalyst (CPRX) Up 14.7% Since Last Earnings Report: Can It Continue? - Yahoo Finance

Mar 28, 2025
pulisher
Mar 28, 2025

RNA Biotechs: Current State And Outlook - Seeking Alpha

Mar 28, 2025
pulisher
Mar 27, 2025

Ionis and Sobi agree on olezarsen commercialisation - Yahoo

Mar 27, 2025
pulisher
Mar 26, 2025

Ionis licenses olezarsen to Sobi for global reach By Investing.com - Investing.com South Africa

Mar 26, 2025
pulisher
Mar 26, 2025

Ionis Partners With Sobi to Commercialize Familial Chylomicronemia Syndrome Treatment Outside US - Marketscreener.com

Mar 26, 2025
pulisher
Mar 26, 2025

Ionis Expands Partnership With SOBI To Include Olezarsen Commercialization Outside The U.S. - Marketscreener.com

Mar 26, 2025
pulisher
Mar 26, 2025

Ionis licenses olezarsen to Sobi for global reach - Investing.com

Mar 26, 2025
pulisher
Mar 26, 2025

First-Ever FCS Treatment: Ionis Expands Global Reach with Major Partnership Deal - Stock Titan

Mar 26, 2025
pulisher
Mar 25, 2025

Is Ionis Pharmaceuticals, Inc. (IONS) a Promising Biotech Stock According to Wall Street Analysts - Insider Monkey

Mar 25, 2025
pulisher
Mar 24, 2025

12 Most Promising Biotech Stocks According to Wall Street Analysts - Insider Monkey

Mar 24, 2025
pulisher
Mar 24, 2025

Ionis Pharmaceuticals’ SWOT analysis: RNA pioneer’s stock faces pivotal year - Investing.com

Mar 24, 2025
pulisher
Mar 24, 2025

Ionis Rings the Opening Bell - Nasdaq

Mar 24, 2025
pulisher
Mar 24, 2025

Ionis Rings the Nasdaq Stock Market Opening Bell - Nasdaq

Mar 24, 2025
pulisher
Mar 24, 2025

Praxis Precision Medicines to Present on Late-Stage Programs across Epilepsy and Movement Disorders at the American Academy of Neurology 2025 Annual Meeting - GlobeNewswire Inc.

Mar 24, 2025
pulisher
Mar 24, 2025

Lacklustre Performance Is Driving Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) Low P/S - simplywall.st

Mar 24, 2025
pulisher
Mar 21, 2025

Why Is Ionis Pharmaceuticals (IONS) Up 0.1% Since Last Earnings Report? - Yahoo Finance Australia

Mar 21, 2025
pulisher
Mar 20, 2025

Multiple System Atrophy Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Ionis Pharma, Biohaven Pharma, Lundbeck A/S, Alterity Therapeutics, Theravance Biopharma, Ionis Pharma - Barchart

Mar 20, 2025
pulisher
Mar 20, 2025

Multiple System Atrophy Market to Reach New Heights in Growth - openPR

Mar 20, 2025
pulisher
Mar 19, 2025

Familial Chylomicronemia Syndrome Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies - The Globe and Mail

Mar 19, 2025
pulisher
Mar 18, 2025

Spinocerebellar Ataxias Pipeline 2025: Therapies, MOA - openPR

Mar 18, 2025
pulisher
Mar 18, 2025

Ionis Pharmaceuticals at UBS Virtual CNS Day: Neurology Pipeline Insights By Investing.com - Investing.com UK

Mar 18, 2025
pulisher
Mar 17, 2025

Opinion: Angelman Syndrome Race Heats Up Among Ionis, Ultragenyx and Neuren - BioSpace

Mar 17, 2025
pulisher
Mar 14, 2025

IONS/AZN Get FDA Nod for Amyloidosis Drug, Wainzua in Europe - MSN

Mar 14, 2025
pulisher
Mar 14, 2025

Retinitis Pigmentosa Pipeline 2024: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight | Biogen, Neurotech, Ionis Pharma, Nacuity Pharma, Allegro Ophthalmics - Barchart

Mar 14, 2025
pulisher
Mar 14, 2025

Ionis Pharmaceuticals CEO Monia sells $4,524 in stock By Investing.com - Investing.com Australia

Mar 14, 2025
pulisher
Mar 14, 2025

Charles Schwab Investment Management Inc. Purchases 38,420 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) - Defense World

Mar 14, 2025
pulisher
Mar 13, 2025

Chief Executive Officer Monia Brett P sold $4,525 worth of shares (140 units at $32.32), decreasing direct ownership by 0.08% to 180,980 units (SEC Form 4) - Quantisnow

Mar 13, 2025
pulisher
Mar 13, 2025

Ionis Pharmaceuticals CEO Monia sells $4,524 in stock - Investing.com India

Mar 13, 2025
pulisher
Mar 12, 2025

Ionis Gets Tryngolza Launch Cash From Ono Via Sapablursen License - Citeline

Mar 12, 2025
pulisher
Mar 12, 2025

Ionis Pharmaceuticals at Barclays Conference: Strategic Growth and Partnerships By Investing.com - Investing.com UK

Mar 12, 2025
pulisher
Mar 12, 2025

Arrowhead Pharmaceuticals Stock Falls After Early-Stage Data From RNA-Based Therapeutic For Kidney Diseases - AOL

Mar 12, 2025
pulisher
Mar 12, 2025

Ono earmarks $940m to gain rare blood cancer therapy from Ionis - Yahoo

Mar 12, 2025
pulisher
Mar 12, 2025

Ionis Pharmaceuticals Partners With Japan-Based Ono Pharmaceutical For Rare Blood Disease Drug In Over $800 Million Deal - AOL

Mar 12, 2025
pulisher
Mar 12, 2025

Ono partners with Ionis for sapablursen - The Pharma Letter

Mar 12, 2025
pulisher
Mar 12, 2025

Ono pays $280M to license Ionis rare disease drug - BioPharma Dive

Mar 12, 2025
pulisher
Mar 12, 2025

Oppenheimer maintains Outperform on Ionis, $78 target By Investing.com - Investing.com UK

Mar 12, 2025
pulisher
Mar 12, 2025

Ionis out licenses blood disorder therapy to Ono in a deal worth up to $940M - MSN

Mar 12, 2025
pulisher
Mar 12, 2025

Ionis Out-Licenses Rights for Rare Blood Cancer Drug to Ono - Zacks Investment Research

Mar 12, 2025
pulisher
Mar 12, 2025

Ionis Pharmaceuticals Enters Global License Agreement With Ono Pharmaceutical for Sapablursen - Marketscreener.com

Mar 12, 2025
pulisher
Mar 12, 2025

Jones Financial Companies Lllp Has $326,000 Stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) - Defense World

Mar 12, 2025
pulisher
Mar 12, 2025

Ionis Pharmaceuticals (NASDAQ:IONS) Price Target Cut to $47.00 by Analysts at JPMorgan Chase & Co. - Defense World

Mar 12, 2025
$70.69
price down icon 1.05%
$76.29
price down icon 2.18%
$31.13
price down icon 0.77%
$19.29
price down icon 5.07%
$91.06
price down icon 4.10%
biotechnology ONC
$272.17
price up icon 1.79%
大文字化:     |  ボリューム (24 時間):